SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance by Leiner, Tim et al.
Leiner et al. J Cardiovasc Magn Reson           (2020) 22:76  
https://doi.org/10.1186/s12968-020-00682-4
REVIEW
SCMR Position Paper (2020) on clinical 
indications for cardiovascular magnetic 
resonance
Tim Leiner1*, Jan Bogaert2,3, Matthias G. Friedrich4, Raad Mohiaddin5,6, Vivek Muthurangu7, Saul Myerson8, 
Andrew J. Powell9,10, Subha V. Raman11 and Dudley J. Pennell12,13
Abstract 
The Society for Cardiovascular Magnetic Resonance (SCMR) last published its comprehensive expert panel report of 
clinical indications for CMR in 2004. This new Consensus Panel report brings those indications up to date for 2020 and 
includes the very substantial increase in scanning techniques, clinical applicability and adoption of CMR worldwide. 
We have used a nearly identical grading system for indications as in 2004 to ensure comparability with the previous 
report but have added the presence of randomized controlled trials as evidence for level 1 indications. In addition to 
the text, tables of the consensus indication levels are included for rapid assimilation and illustrative figures of some 
key techniques are provided.
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Introduction
Cardiovascular magnetic resonance (CMR) is established 
in clinical practice for the diagnosis and management of 
diseases of the cardiovascular system. However, current 
guidelines for when this technique should be employed 
in clinical practice have not been revised since the pre-
vious Consensus Panel report of 2004 [1]. Considerable 
technical and practice advances have been made in the 
intervening years and the level of interest from clinicians 
in this field is at an unprecedented level. This Consen-
sus Panel report updates these guidelines. As CMR is a 
multidisciplinary technique with international interest, 
the Consensus Panel was composed of European and 
American cardiologists and radiologists, all of whom are 
internationally recognized experts in the field of CMR, 
actively practice CMR and have played important roles 
in its development and clinical application. The coordi-
nating authors (Leiner and Pennell) assembled the list 
of experts at the request of the Society for Cardiovas-
cular Magnetic Resonance (SCMR) Executive Commit-
tee, ensuring coverage of all classes of indications. This 
list was subsequently approved by the SCMR Executive 
Committee as well as the Board of Trustees prior to the 
start of the writing process. The Consensus Panel was 
originated, approved and funded in its activities by the 
SCMR.
The Consensus Panel recommendations are based on 
evidence compiled from the literature and expert experi-
ence. Consensus on the evidence classes was achieved by 
a modified Delphi process. First the section (co-)authors 
suggested evidence classes for the indications in their 
respective sections. These were reviewed by all other 
authors in at least three written rounds of commentary. 
Evidence classes were finalized with all authors of the 
documents present in a telephone conference. When 
insufficient evidence is present in the literature, this is 
indicated in the report and recommendations are made 
conservatively under these circumstances. The appro-
priateness of using CMR is described for the frequent 
disease entities where imaging information may be war-
ranted. The diagnostic use of CMR will be described in 
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the context of other, competing  non-invasive imaging 
techniques, with particular emphasis on the differential 
indications with respect to echocardiography.
The usefulness of CMR in specific diseases is summa-
rized by means of the following classification:
Class I = provides clinically relevant information and 
is usually appropriate; may be used as first line imag-
ing technique; usually supported by substantial litera-
ture or randomised controlled trial(s).
Class II = provides clinically relevant information 
and is frequently useful; other techniques may pro-
vide similar information; supported by limited lit-
erature.
Class III = provides clinically relevant information 
but is infrequently used because information from 
other imaging techniques is usually adequate.
Class Inv = potentially useful, but still investigational.
This classification is not meant to equate to American 
Heart Association/American (AHA), American College 
of Cardiology (ACC) and European Society of Cardiology 
(ESC) consensus documents. We have used nearly the 
identical classification system that was used for the origi-
nal Consensus Panel report of 2004, in order to maintain 
parity with that report so that advances in the field can be 
readily identified. Because of broad variation in the num-
ber of relevant papers between topics, we did not use an 
arbitrary number of papers for each class. Class 1 indica-
tions required the highest level of evidence, for example 
affirmative randomized controlled trials (RCT) results for 
use of perfusion CMR. The categories were populated by 
consensus. The quality of the publications (impact factor, 
RCT or not, etc.) was germane to the Consensus Panel 
discussion of ranking of class throughout the discussions. 
Thus, the only change from 2004 is to add the positive 
outcome of RCTs in CMR as evidence for level 1 indica-
tions. It should also be noted that the classification sys-
tem for imaging technologies does not easily accord with 
that of therapeutic trials because the datasets are smaller, 
multicentre trials are uncommon and randomized con-
trolled trials the exception. The continuing technical and 
clinical advances in CMR will change the indication’s 
tables, and therefore between formal reports, the Con-
sensus Panel may post updates online.
Congenital heart disease
CMR is a well-established modality for the diagnosis 
and follow-up of patients with congenital heart disease 
(CHD) (Table 1). This is because it provides unrestricted 
evaluation of the intracardiac and vascular anatomy, and 
reference standard measurements of the ventricles and 
blood flow. In general, transthoracic echocardiography 
(TTE) continues to be used as the first-line method 
of assessing cardiovascular anatomy and function in 
patients with CHD. However, when acoustic window lim-
itations preclude an adequate assessment or more reli-
able quantification of ventricular parameters and blood 
flow is required, CMR is often indicated. In addition, the 
tissue characterization capabilities of CMR (e.g. fibro-
sis detection) can have a significant impact on patient 
management [2–6]. CMR has also been used to replace 
invasive  diagnostic catheterization for assessment of 
CHD as it provides comparable anatomic information 
without exposure to ionizing radiation or the risks of an 
invasive procedure [7, 8]. CMR’s advantages over com-
puted tomography (CT) include again the avoidance of 
ionizing radiation along with superior ventricular func-
tion assessment, blood flow measurement, and tissue 
characterization.
When performing CMR in CHD patients, it is impor-
tant to tailor the acquisition parameters to the faster 
heart rates and smaller structures in children, as well as 
the limited breath-holding ability of children and poorly 
compensated adult CHD patients. It is also necessary 
to have thorough knowledge of CHD anatomy and the 
extensive array of surgical and catheter interventions. 
Therefore, it is highly recommended that CMR in CHD 
patients is performed in centers with sufficient experi-
ence and expertise.
General
In younger children with CHD, TTE is often sufficient for 
initial diagnosis. However, CMR can provide important 
additional information in lesions with complex intra-
cardiac anatomy or vascular abnormalities. In adults 
with CHD, TTE is often limited by poor image quality 
and reduced field of view. Thus, CMR with its reliable 
visualization of intracardiac and vascular anatomy takes 
on a central role in the routine non-invasive imaging 
of these patients. This indication has been recognized 
in recent guidelines regarding multi-modality imag-
ing and the management of adults with CHD [9–11]. 
Another key indication for CMR in CHD is the assess-
ment of ventricular volumes, mass, and function. The 
clear delineation of endocardial and epicardial borders, 
and ability to quantify without geometric assumptions 
have established CMR as the clinical reference standard 
[12–14]. The advantages of CMR are particularly valuable 
for right ventricular (RV) assessment as its retrosternal 
position and complex shape make it difficult to reliably 
assess by TTE. This capability is especially relevant in 
CHD as many lesions are associated with a RV pressure 
or volume load. Several studies have demonstrated good 
reproducibility of RV measurements by CMR in CHD 
underscoring its suitability for serial assessment [15–18]. 
Page 3 of 37Leiner et al. J Cardiovasc Magn Reson           (2020) 22:76  
A final important general indication for CMR is assess-
ment of blood flow. Multiple studies have shown that it 
provides accurate measurement of cardiac output and 
the pulmonary-to-systemic flow (Qp:Qs) ratio compared 
to invasive techniques [19–21].
Shunt lesions
For shunt lesions, CMR is used to delineate anatomy and 
determine physiological importance through measure-
ment of the Qp:Qs ratio and ventricular volumes. This is 
vital information for determining the necessity and tim-
ing of surgical or catheter interventions. Studies have 
shown that CMR can provide definitive diagnosis and 
evaluation of sinus venosus defects and anomalous pul-
monary venous connection [22, 23] (Fig.  1). This is rel-
evant as these lesions are difficult to image with TTE, 
particularly in older patients. Several studies have also 
shown that CMR provides a comprehensive evaluation of 
the morphology and physiological importance of secun-
dum atrial septal defects, and can determine candidacy 
for transcatheter or surgical closure [24–26]. CMR may 
be especially useful in adult patients who have find-
ings (e.g., murmur or RV dilation) that raise a suspicion 
for an atrial septal defect or other shunt lesion that is 
Table 1 Indications for CMR in congenital heart disease
C: children; A: adult
a For non-congenital valve lesions in adults, please refer to Table 7
Indication Class
1. General
   Initial evaluation and follow-up of congenital heart disease C II/A I
   Evaluation of right and left ventricular volumes, mass, and function I
   Measurement of the pulmonary-to-systemic flow ratio I
2. Shunts lesions
   Patent foramen ovale III
   Atrial septal defects C III/A II
   Sinus venosus defects I
   Anomalous pulmonary venous connection I
   Ventricular septal defects C III/A II
   Atrioventricular septal defects C III/A II
   Patent ductus arteriosus C III/A II
   Aorto-pulmonary window C III/A II
   Systemic-to-pulmonary artery collaterals I
3. Valve  lesionsa
   Tricuspid valve disease, including Ebstein disease II
   Pulmonary valve disease II
   Mitral valve disease III
   Aortic valve disease II
4. Arterial lesions
   Aortic coarctation and interrupted aortic arch C II/A I
   Vascular rings I
   Supravalvular aortic stenosis C III/A II
   Coronary anomalies C II/A I
   Pulmonary artery stenosis C II/A I
5. Conotruncal lesions
   Tetralogy of Fallot C II/A I
   Double outlet right ventricle I
   D-loop transposition of the great arteries C II/A I
   Congenitally corrected transposition of the great arteries I
   Truncus arteriosus I
6. Complex disease
   Heterotaxy syndrome I
   Single ventricle heart disease I
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not definitively resolved by TTE. Here, CMR provides 
a non-invasive alternative to transesophageal echocar-
diography (TEE) with better sensitivity for anomalous 
pulmonary venous connections. Patent foramen ovale is 
usually diagnosed with echocardiography though there 
are CMR techniques to address this question [27, 28]. 
Ventricular septal defects are generally diagnosed and 
managed using echocardiography. However, CMR with 
3D imaging may be useful for delineation of complex or 
multiple defects [29]. In addition, CMR measurement of 
the Qp:Qs ratio and left ventricular (LV) volume may be 
important in determining management in older children 
and adults [9]. Most patients with atrioventricular septal 
defects are diagnosed in childhood by TTE and undergo 
surgical repair. Subsequently, atrioventricular valve 
regurgitation may develop and CMR provides a reliable 
quantitative assessment of its severity [30, 31] and insight 
into its mechanism [32]. Patent ductus arteriosus and 
aorto-pulmonary window typically present in infancy 
where echocardiography is usually adequate for diagno-
sis and management. When this evaluation is insufficient 
or the patient is older, CMR techniques can be used to 
define the vascular anatomy and assess the magnitude of 
the shunt. In patients with systemic-to-pulmonary artery 
collaterals, CMR can be used to quantify the amount of 
collateral flow [33, 34] and identify larger vessels that 
may be suitable for catheter interventions.
Valve lesions
CHD may be associated with abnormalities in the cardiac 
valves. Echocardiography is often the primary modal-
ity for assessing valve morphology and function. CMR is 
principally used to evaluate the physiological impact of 
valve regurgitation by measuring the regurgitation vol-
ume, regurgitant fraction, and ventricular size and func-
tion. This information plays an important role in deciding 
the timing of mechanical interventions. With valve ste-
nosis, CMR can be used to define orifice size [35] but 
may underestimate the peak velocity and estimated pres-
sure gradient [36]. In unrepaired Ebstein’s anomaly, CMR 
assessment of the abnormal tricuspid valve leaflets, tri-
cuspid regurgitation, and RV volumes and function can 
be used to determine the suitability for operative repair 
[37, 38] and predict major adverse cardiac events and 
atrial arrhythmia [39]. Following repair, CMR can dem-
onstrate the extent of ventricular remodeling [40, 41].
Arterial lesions
Congenital abnormalities of the aorta, pulmonary arter-
ies, and coronary arteries may occur in isolation or in 
association with other CHD lesions. The ability to assess 
these structures by echocardiography becomes progres-
sively more difficult as patients become larger, and CMR 
angiography techniques serve as an important non-
invasive alternative [42–44]. In coarctation of the aorta, 
CMR is used for assessment before and after intervention 
(Fig. 2). In addition to delineating the anatomy [45], CMR 
provides information on severity through assessment of 
the peak velocity at the obstruction site, extent of collat-
eral flow, and ventricular hypertrophy [46–51]. In adults, 
the combination of clinical assessment and CMR has 
been shown to provide a better “cost-effective” yield com-
pared with a combination that relies on echocardiogra-
phy as the primary imaging modality [52]. Vascular rings 
Fig. 1 Balanced steady state free precession (bSSFP) cine images through a superior sinus venosus defect (*): a sagittal oblique view, b transverse 
oblique also showing anomalously draining right pulmonary veins
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can be fully delineated using CMR, including the trachea 
and main bronchi to identify associated compression [53, 
54]. CMR reliably depicts congenital abnormalities in the 
course of the proximal coronary arteries [55, 56], and 
diagnosis has been shown to predict major adverse car-
diac events [57]. Compared to X-ray angiography, CMR 
better demonstrates the coronary course with respect to 
the semilunar valves [58], which is crucial for risk-strati-
fication and surgical planning. CMR provides an accurate 
assessment of main and branch pulmonary artery dimen-
sions [44]. In the setting of branch pulmonary artery ste-
nosis, it can quantify differential lung perfusion [59, 60], 
which has been shown to better predict symptoms than 
anatomic measurements [61]. Lastly, CMR has been used 
to diagnose supravalvar aortic stenosis and characterize 
its physiological importance [62].
Conotruncal lesions
Conotruncal lesions include tetralogy of Fallot, transpo-
sition of the great arteries (TGA), double outlet RV, and 
truncus arteriosus, among others. The primary imag-
ing modality for these conditions in younger children is 
echocardiography. CMR may augment the preoperative 
assessment of double outlet RV by better characterizing 
the intracardiac anatomy, particularly through use of vir-
tual and 3D printed models [29, 63]. CMR can also be 
used define the pulmonary blood supply including aorto-
pulmonary collaterals in patients with complex pulmo-
nary stenosis or atresia [8]. In older children and adults 
with repaired conotruncal lesions, CMR assumes an 
important role as the clinical concerns often involve the 
pulmonary arteries, aorta, coronary arteries, pulmonary 
valve, intracardiac baffles, and RV, all relative strengths 
compared to echocardiography. In patients with repaired 
tetralogy of Fallot, CMR-derived parameters inform 
risk-stratification [3, 64–66] and referral for pulmonary 
valve replacement [67–69], and figure prominently in 
published clinical management guidelines [9–11, 70]. In 
patients with d-loop TGA who have undergone an atrial 
switch procedure, CMR is used to evaluate the atrial baf-
fles, and systemic RV volumes, function [18], and scar 
[2]; abnormal findings have been shown to predict out-
come [71]. For d-loop TGA patients who have had an 
arterial switch operation, CMR indications include moni-
toring for pulmonary artery stenosis, semilunar valve 
regurgitation, and coronary artery obstruction [72–74]. 
Congenitally-corrected TGA patients require CMR for 
surveillance of their systemic RV; those who are post-
operative need assessment of intracardiac baffles, arterial 
conduits, coronary stenosis, and ventricular function [75, 
76]. The surgical repair of patients with truncus arterio-
sus as well as other conotruncal lesions may include the 
placement of a ventricle-to-pulmonary artery conduit 
and these are prone to develop stenosis and regurgita-
tion over time. TTE imaging is often difficult due to the 
retrosternal position of the conduit while CMR provides 
accurate anatomic and functional assessment [75–78].
Complex lesions
The reliable visualization of intracardiac and vascular 
anatomy, large field of view, and 3D imaging capabilities 
all make CMR well-suited for the diagnosis of complex 
cardiovascular anatomic arrangements, such as those 
seen in more severe forms of heterotaxy syndrome [79, 
Fig. 2 Multiple CMR methods of imaging coarctation of the aorta: a sagittal oblique 2D black blood, b maximal intensity projection gadolinium 
enhanced CMR angiogram (CMRA) and c volume rendering of gadolinium enhanced CMRA
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80]. CMR is a non-invasive alternative to invasive  car-
diac catheterization and often provides a more compre-
hensive evaluation than echocardiography. CMR also has 
an important role in the diagnostic evaluation and serial 
follow-up of patients with single ventricle heart disease. 
TTE is the primary imaging tool during the initial evalu-
ation since most patients present in the newborn period 
and their acoustic windows are typically adequate; in 
some cases, CMR may be used to determine whether a 
one versus two-ventricle repair should be pursued [81, 
82]. Studies have shown that later in their course, CMR 
outperforms TTE and can substitute for routine diag-
nostic catheterization in selected patients prior to the 
bidirectional Glenn shunt or a hemi-Fontan procedure 
(second-stage palliation) [7, 83–85], and prior to the Fon-
tan procedure (third-stage palliation) [86–88]. Moreover, 
CMR measurements of systemic-to-pulmonary artery 
collateral flow predict post-operative outcomes such 
as hospital length of stay [89–91]. Following the Fontan 
procedure, patients remain at risk for numerous compli-
cations including ventricular and valve dysfunction, Fon-
tan baffle obstruction, pulmonary artery stenosis, aortic 
coarctation, systemic-to-pulmonary venous collateral 
formation, and intracardiac thrombus formation. CMR 
has a key role in surveillance for these complications as 
the evaluation by TTE alone is often incomplete [92, 93]. 
Finally, CMR-derived parameters such as ventricular vol-
ume and myocardial fibrosis have been shown to be asso-
ciated with adverse outcomes [5, 94].
Acquired vascular disease
CMR is a highly reliable modality for depiction of the 
presence and extent of acquired vascular disease in virtu-
ally all of the large and medium sized arteries in the body 
(Table 2). A variety of techniques exist to depict both the 
vascular lumen as well as the vessel wall. The current 
standard of reference is contrast-enhanced (CE) CMRA. 
CE-CMRA is obtained during first arterial passage of an 
Table 2 Indications for CMR in acquired diseases of the vasculature
Indication Class
1. Diagnosis and follow-up of thoracic aortic aneurysm including connective tissue diseases I
2. Diagnosis and planning of stent treatment for abdominal aortic aneurysm II
3. Follow-up of stented abdominal aortic aneurysm III
4. Aortic dissection
  Diagnosis of acute aortic dissection II
  Diagnosis and follow-up of chronic aortic dissection I
5. Diagnosis of aortic intramural hematoma I
6. Diagnosis of penetrating aortic ulcers I
7. Pulmonary artery anatomy and flow I
8. Pulmonary emboli
  Diagnosis of central pulmonary emboli III
  Diagnosis of peripheral pulmonary emboli III
  Assessment of chronic pulmonary embolic disease III
9. Assessment of aortic arch arteries I
10. Assessment of aortic branch arteries including the Adamkiewicz artery II
11. Assessment of carotid, vertebral and circle of Willis arteries I
12. Assessment of upper extremity arteries I
13. Assessment of hand arteries II
14. Assessment of renal arteries I
15. Assessment of mesenteric arteries I
16. Assessment of pelvic and lower extremity arteries I
17. Assessment of pulmonary veins I
18. Assessment of thoracic, abdominal and pelvic veins I
19. Assessment of lower extremity veins I
20. Assessment of atherosclerotic plaque in the carotid artery II
21. Assessment of atherosclerotic plaque in the aorta II
22. Assessment of vascular wall inflammation in large and medium sized arteries II
23. Assessment of aortic pulse wave velocity Inv
24. Endothelial function Inv
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intravenous bolus injection of gadolinium-based con-
trast agents (GBCA). On modern CMR scanners, virtu-
ally all CE-CMRA applications can be performed with a 
single dose of contrast agent (0.1  mmol/kg). If the area 
of interest exceeds a single field-of-view (FOV), as is the 
case for total body or lower extremity artery imaging, a 
moving table protocol can be used whereby the contrast 
bolus is followed over multiple FOV by rapid table move-
ment. Typical spatial resolution is in the order of 1.0 × 1.0 
(in-plane) × 1.0–2.0 (slice thickness)  mm3. On modern 
hardware this high spatial resolution can be obtained 
in a single breath hold, which is necessary for chest and 
abdominal CE-CMRA. For some clinical indications it 
is advisable to use a multi-phase dynamic acquisition 
as this can provide information about the direction of 
blood flow as well as information about tissue perfusion. 
Since dynamic CE-CMRA demands a higher temporal 
resolution this typically comes at the expense of spatial 
resolution. In selected cases it can therefore be useful to 
perform both acquisitions with two separate injections of 
contrast agent. Although the vast majority of CE-CMRA 
studies are performed with GBCA, a substantial body of 
literature has been published on the use of ferumoxy-
tol as a CMRA contrast agent. Ferumoxytol is an intra-
venous iron preparation for treatment of the anemia of 
chronic kidney disease [95]. It is a carbohydrate-coated, 
superparamagnetic iron oxide nanoparticle that leads 
to prolonged intravascular enhancement when patients 
are imaged with CE-CMRA sequences. Ferumoxytol-
enhanced CE-CMRA can be obtained with much higher 
spatial resolution due to the much longer intravascular 
half-life of this contrast agent [96]. This pharmacokinetic 
profile can be advantageous when both high spatial reso-
lution as well as cardiac and/or respiratory synchroniza-
tion is desired, or in patients with contra-indications for 
administration of GBCA.
Over the past few years all major hardware vendors 
have also introduced non-contrast or native CMRA 
sequences on their platforms. These sequences utilize 
intrinsic contrast between flowing blood and station-
ary tissues as the basis to generate angiograms. Different 
technical approaches are also well described [97]. Major 
advantages of non-contrast CMRA include cost-savings 
and improved patient safety. They are also the optimal 
CMR technique for assessing aortic dissection as the dis-
section flap in better visualized than with CE-CMRA. 
Disadvantages include the slightly longer time needed for 
acquisition (several minutes compared to < 1 min for CE-
CMRA), marginally lower spatial resolution, and reduced 
ability to provide 3D surface rendered images.
In addition to angiography, the wide variety of soft tis-
sue contrast available on CMR (proton density, T1, T2, 
lipid-saturation) can be applied to vascular imaging to 
assess features of vessel wall such as haematoma/throm-
bus, inflammation, and atherosclerotic plaque. In addi-
tion to morphologic imaging of blood vessels, velocity 
mapping can be used to assess and measure the blood 
flow. Blood velocity and flow can be integrated across the 
cardiac cycle and the vessel lumen for reliable volume 
flow measurements. This information is complementary 
to the anatomical information obtained with the lumi-
nographic techniques and can add value in many clinical 
scenarios [98].
Aorta
CMR techniques are well-suited to depict the thoracic 
and abdominal aorta. The high spatial resolution can 
be used for accurate assessment of aortic size, diameter 
and the presence and morphology of aortic aneurysms. 
The near isotropic spatial resolution ensures high quality 
multi-planar reformations (MPRs) which can be used to 
generate an accurate center-lumen line as well as depic-
tion of side branches. Black blood techniques have been 
superseded by CE-CMRA and non-contrast CMRA tech-
niques. The latter technique is particularly useful because 
image acquisition is typically synchronized to the dias-
tolic rest period which greatly improves evaluation of 
the aortic root and leads to sharper aortic wall delinea-
tion because there is no blurring due to vessel pulsatil-
ity (Fig. 3). The advantage of CE-CMRA however is the 
ability to perform a multiphasic acquisition which can 
be used to depict contrast agent dynamics. Post-gadolin-
ium T1-weighted CMR, especially with fat saturation, is 
helpful in identifying areas of peri-aortic inflammation 
in mycotic aneurysms or suspected vasculitis [99–101]. 
Inflammatory aortic aneurysms can have a thick rind of 
tissue encircling the anterior and lateral aspects of the 
aorta, which typically enhances with gadolinium [102]. 
Although not as widely used as CT for pre- and post-
operative evaluation of aortic stent-grafts, CMR pro-
vides comparable information with regard to pre-stent 
anatomy but is more sensitive for detection of post-stent 
leaks for certain stent types [103–105]. A limitation of 
CMR used to be its inability to visualize calcium, which 
is important for stent graft planning. However, a recent 
study has shown the feasibility of a novel CMR sequence 
to accurately depict arterial calcifications with excellent 
agreement to CT angiography (CTA) [106].
Another important component of the aortic imag-
ing protocol is measurement of flow. Although 2D flow 
sequences are still the most widely used technique, there 
is high interest protocols that allow determination of flow 
in a three-dimensional volume over the cardiac cycle 
(also known as ‘4D flow’). This can be particularly inter-
esting in the chest since it enables simultaneous imaging 
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of flow in the cardiac chambers as well as the large vessels 
in a single acquisition [107].
Acute thoracic aortic syndromes include aortic dissec-
tion and limited intimal tear, intramural hematoma and 
penetrating aortic ulcer [108]. Aortic dissection remains 
a well-established indication for CMR although CT may 
be more widely available in the acute setting and dealing 
with acutely ill patients can be complicated in the CMR 
environment. A recent systematic review found that ini-
tial diagnostic evaluation with CMR had a sensitivity of 
95–100% and a specificity of 94–98%, which is compa-
rable to CT and TEE; and superior to TTE or serologic 
biomarkers [109]. Black blood imaging can reveal the 
location and extent of the dissection flap and dynamic 
CE-CMRA can be used assess filling dynamics of the true 
and false lumen. 4D flow imaging can be used to visual-
ize and quantify flow in both lumina as well as through 
any fenestrations (Fig.  4). Due to the outstanding soft 
tissue contrast, imaging of the aortic wall is a particular 
strength of CMR. Intramural hematoma (IMH) is a vari-
ant of dissection, where the false channel in the aortic 
wall is filled with thrombus. No primary dissection flap 
will be visible and two-lumen flow is absent. In IMH 
with hyperacute bleeding,  T2-weighted images display 
Fig. 3 61-year old male followed up after ascending aorta replacment for Stanford type A ascending aortic dissection. Balanced steady state free 
precession (bSSFP) non-contrast CMRA of the ascending aorta synchronized to the diastolic rest period shows the aortic root and origin of the right 
coronary artery without motion artefacts. Note artefacts due to sternal wires
Page 9 of 37Leiner et al. J Cardiovasc Magn Reson           (2020) 22:76  
hyperintense signal in the hematoma, whereas signal is 
isointense on  T1-weighted images. After approximately 
first 24 h, the IMH will appear hyperintense on both  T1- 
and  T2-weighted images. These features help differentiate 
IMH from mural thrombus, which appears hypointense 
or isointense on both  T1- and  T2-weighted sequences 
[110]. The use of fat-saturation techniques is helpful to 
distinguish IMH from the mediastinal fat surrounding 
the aorta. Penetrating atherosclerotic ulcer is a form of 
dissection where there is intimal erosion with ulceration 
extending through the internal elastic lamina into the 
media and/or focal IMH [111, 112]. Penetrating athero-
sclerotic ulcer is a cause of aortic hematoma and should 
be distinguished from ulcer-like projection, which is a 
consequence of the hematoma or thrombus in the wall, 
and only appear after an initial IMH [113]. Differentia-
tion of both entities is crucial since a penetrating athero-
sclerotic ulcer surrounded by an IMH has a higher risk 
of aortic rupture than an IMH complicated with a ulcer-
like projection or localized dissection. A penetrating 
atherosclerotic ulcer with persistent pain, with an IMH 
or periaortic haemorrhage must be treated surgically or 
with thoracic endovascular aortic repair (TEVAR) [112]. 
CE-CMRA may show a focal defect in the arterial intima 
and, typically, deformation of the external aortic contour. 
 T1- and  T2-weighted sequences can demonstrate focal 
IMH as described above.
CMR is also increasingly used to identify aortic ath-
eroma as a potential source of cerebral emboli in cryp-
togenic stroke. A combined protocol using  T1-weighted 
bright blood,  T2- and proton-density weighted black 
blood and 4D flow imaging was recently shown to be 
capable of depicting complex aortic plaque in the aortic 
arch and proximal descending aorta as well as potential 
embolization pathways from such plaques to the brain 
[114].
Carotid and cervical arteries
Carotid artery CE-CMRA is a highly reliable technique 
to depict the presence and extent of atherosclerotic 
plaque formation in the aortic arch branch vessels and 
to measure the degree of carotid artery stenosis [115]. 
Advances in CMR hardware such as dedicated coils and 
the introduction of high spatial and temporal resolution 
CE-CMRA pulse sequences have enabled sub-millim-
eter isotropic voxel sizes in short imaging times using 
K-space view sharing techniques [116]. Venous overlap 
can be avoided by using centric K-space ordering. Prom-
ising results have also been obtained with non-contrast 
enhanced techniques [117].
Pulmonary arteries
Advances in CMR hardware and pulse sequence design 
have enabled high-fidelity depiction of the pulmonary 
arteries and veins in short imaging times [118]. The most 
common acquired disease of the pulmonary arteries is 
pulmonary embolism (PE) and CMRA can function as an 
alternative to CTA to rule out PE. The prospective mul-
ticentre CE-CMRA for pulmonary embolism (PIOPED 
III) study found that a technically adequate protocol that 
combined pulmonary CMRA and CMR venography of 
the peripheral veins has a sensitivity of 92% and a speci-
ficity of 96% compared to the reference standard [119]. 
However, in this study a large proportion of examinations 
were technically inadequate due to motion artefacts and 
inadequate vascular opacification [120]. For this reason, 
CMRA of the pulmonary arteries should only be consid-
ered in at centers that routinely perform it and in patients 
in whom standard tests (e.g., CTA)  are contraindicated. 
A more recent study that combined a non-contrast and 
CE protocol found CMR to be practically equivalent to 
pulmonary CTA in patients with suspected thrombo-
embolism [121]. Pulmonary artery CMRA remains the 
technique of choice for integrated cardiopulmonary 
evaluation of acquired pulmonary artery stenosis [122], 
evaluation of pulmonary artery aneurysms [123] and dis-
section [124].
Fig. 4 4D flow CMR velocity maximal intensity projection (MIP) (A) 
and time-resolved CMRA (TR-CMRA) MIP in a patient with type B 
aortic dissection. While TR-CMRA demonstrates dynamic filling of the 
proximal false lumen (FL), 4D flow exhibits a prominent entry tear jet 
impinging on the wall of the distal arch (white arrow). At least one 
smaller hemodynamically active fenestration is also seen more distal 
to the primary entry tear (arrowhead). TL: true lumen. Figure courtesy 
of Bradley D. Allen, MD MS, and Michael Markl, Ph.D., Northwestern 
University, Chicago, IL
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Abdominal aorta, renal and mesenteric arteries
CE-CMRA remains the technique of choice for imag-
ing the abdominal aorta and its branches. The ability 
to obtain high spatial resolution images of these vessels 
within a single breath hold enables accurate depiction 
of stenosis in the abdominal aorta, renal and mesenteric 
arteries [125]. CMRA is also well-suited to characterize 
aneurysmal disease of the abdominal aorta. The excellent 
soft tissue contrast facilitates detection and characteriza-
tion of both the vascular lumen as well as mural throm-
bus. A combined CMRA and abdominal CMR protocol 
can even be used in patients with some types of abdomi-
nal aortic stents to assess the presence of endoleak after 
endovascular aortic aneurysm repair and has been shown 
to outperform multiphasic CTA for this purpose [104, 
105].
For many years CE-CMRA has been an accepted 
modality to depict the renal arteries. Renal artery CMRA 
is used to visualize the number and course of the renal 
arteries prior to nephrectomy and dynamic CE sequences 
can be added to the imaging protocol to quantify renal 
perfusion [126]. However, since publication of the Car-
diovascular Outcomes in Renal Atherosclerotic Lesions 
(CORAL) [127] and the Angioplasty and Stenting for 
Renal Artery Lesions (ASTRAL) [128] trials which both 
demonstrated that subjects with renal artery stenosis had 
similar outcomes whether randomized to optimal medi-
cal therapy alone or optimal medical therapy plus renal 
artery stenting, clinical interest in imaging renal artery 
stenosis has decreased. On the other hand, the introduc-
tion of renal sympathetic denervation [129, 130] has led 
to a renewed interest in imaging of renal artery anatomy 
and non-invasive imaging of renal function. The ability to 
simultaneously depict renal anatomy and physiology as 
well as cardiac function also allows unique insights into 
cardiorenal function [131]. Stenosis of the celiac trunk 
and mesenteric arteries can also be reliably diagnosed 
with CMRA techniques. Although CTA is preferred in 
the acute setting, both techniques can be used to depict 
the degree of atherosclerotic narrowing and presence 
and extent of collateral circulation, as well as other non-
atherosclerotic vascular pathologies such as fibromus-
cular dysplasia and compression of the celiac trunk by 
a median arcuate ligament [132]. In the latter condition 
CMRA is preferred as it allows for obtaining both inspir-
atory and expiratory views of the celiac trunk without 
radiation burden.
Lower extremity arteries
CMRA has been shown to be a highly reliable technique 
to depict the presence and extent of arterial narrowing in 
patients with intermittent claudication and chronic criti-
cal ischemia [133–136]. In most patients, atherosclerotic 
peripheral arterial occlusive disease is the underlying 
cause of arterial narrowing. The imaging protocol typi-
cally consists of acquisition of 3–4 FOVs or ‘steps’ during 
infusion of 0.1–0.2 mmol/kg contrast agent. Such proto-
cols enable depiction of the peripheral vasculature from 
the aorta down to the feet with high vessel to background 
contrast [137–139]. The separate acquisitions are then 
‘stitched’ together to provide a comprehensive overview 
of the peripheral vascular tree (Fig.  5). In patients with 
chronic critical ischemia the lower leg and pedal vascula-
ture may be compromised by venous contamination. To 
avoid this problem, it is recommended to use a separate 
low-dose injection of contrast medium in combination 
with a time-resolved acquisition. Not only does this avoid 
the problem of venous overlay, but it also provides hemo-
dynamic information about the flow direction in severely 
diseased arteries and it enables high-quality imaging of 
small, distal vessels in patients with differential flow in 
the lower extremities. To further optimize depiction of 
the small distal arteries it is desirable to use fat suppres-
sion. This can be done by subtraction of non-contrast-
enhanced ‘mask’ images, or by using pulse sequences 
such as the modified Dixon technique [104]. The out-
standing soft tissue contrast of CMR also enables diag-
nosis of alternative vascular pathologies that may lead to 
intermittent claudication such as popliteal entrapment, 
vasculitis, cystic adventitial disease, fibromuscular dys-
plasia and other more uncommon diseases [140].
Recently, significant advances have been made in non-
contrast CMRA of the peripheral vessels. Promising 
results have been obtained with quiescent interval single 
shot (QISS) CMRA. In a study in 53 patients with sus-
pected or known peripheral arterial disease the diagnos-
tic performance of QISS CMRA was shown to be nearly 
equivalent to CE-CMRA and digital subtraction angiog-
raphy [141]. The same investigators also demonstrated 
the ability to depict areas in the arterial vessel wall con-
taining calcium deposits [142], which further enhances 
the attractiveness of CMR as an alternative to CT.
Arterial wall imaging
The ability to null blood signal provides important 
opportunities for detection and characterization of vessel 
wall abnormalities with CMR. This does not only concern 
imaging of atherosclerotic plaque, but also inflammatory 
changes associated with vasculitis and rheumatologi-
cal diseases. CMR vessel wall imaging has been shown 
to be capable of detecting, characterizing and quantify-
ing atherosclerotic plaque in the aorta [143, 144], carotid 
arteries [145, 146], lower extremity arteries [147, 148] 
and even the coronary [149, 150] and intracranial arter-
ies [151, 152]. The large FOV allows depiction of arte-
rial wall changes over large anatomical trajectories. The 
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imaging protocol typically consists T1-, T2- and proton 
density weighted images which enables identification of 
lipid-rich necrotic core and intra-plaque haemorrhage 
– the two most important features that portend plaque 
rupture and clinical sequelae –with high sensitivity and 
specificity [146]. More recently, combined angiographic 
and black blood imaging sequences have been described 
that allow fast, simultaneous imaging of the vasculature 
as well as the presence of intraplaque haemorrhage [153]. 
T1 and T2 vessel wall mapping protocols are now also 
becoming available and may remove some of the subjec-
tivity of conventional T1- and T2-weighted sequences 
[154].
In patients with suspected or known large and 
medium vessel vasculitis, 3D fat-suppressed black-blood 
T1-weighted turbo spin-echo sequences have been of 
particular value to depict inflammatory changes such as 
post-contrast vessel wall enhancement in the aorta and 
its branches [144], extra- and intracranial carotid artery 
and its branches [155, 156], as well as the cerebral arter-
ies [157].
Pulse wave velocity
Early atherosclerotic changes in the arterial wall lead 
to outward remodelling and are not yet visible as lumi-
nal narrowing, which limits the utility of angiographic 
techniques. Pulse wave velocity (PWV) is a biomarker of 
arterial stiffness, which is known to increase long before 
the advent of stenosis. CMR is the technique of choice to 
measure PWV because it is a highly reliable for measure-
ment of vessel length and vascular velocity waveforms 
at different locations in a vessel. The pulse wave can be 
understood as a wave superimposed on the flow/pressure 
waveform of the blood. This superimposed pulse wave 
accelerates and decelerates as it traverses distally in the 
vasculature relative to the stiffness of the vessel in a given 
segment [158]. PWV is arguably one of the earliest mark-
ers of atherosclerosis and alterations in aortic PWV have 
been shown to be related to the level of insulin resistance 
in children with type-1 diabetes mellitus [159], to blood 
pressure, body mass index and levels of expression of cel-
lular adhesion molecules [160] in young adults [161], as 
well as cognitive decline in the elderly [162].
Arterial reactivity
Another CMR based method to non-invasively assess 
vascular function is artery reactivity. Endothelial function 
can be examined non-invasively with stimuli which cause 
arterial vasodilation. Flow mediated dilation is used to 
examine endothelial function directly, by occluding usu-
ally the forearm using a blood pressure cuff inflated 
above systolic pressure for a standard time period. On 
release of the cuff, reactive hyperaemia causes increased 
Fig. 5 65-year-old man with bilateral Fontaine IIb peripheral arterial 
disease. There are bilateral common femoral artery occlusions 
bridged by collaterals, as well as an occluded superficial femoral 
artery in the left leg. Collateral arteries bridge the common femoral 
arteries. The right superficial femoral artery shows a high-grade 
stenosis (arrowhead). The tibioperoneal trunk and proximal posterior 
tibial artery are clearly patent (horizontal arrow). There is subtle 
narrowing of the proximal right renal artery (oblique arrow)
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endothelial shear and the release of nitric oxide which 
causes the brachial artery to dilate. Endothelial inde-
pendent responses can also be tested by using glyceryl 
trinitrate, typically as a sublingual spray. Visualisation of 
brachial dilation with these stimuli was first described 
using ultrasound [163], but it may be difficult to ensure 
that the transducer is correctly positioned perpendicular 
to the artery and without movement, and that repeated 
measurements are made with good reproducibility. CMR 
techniques are considered to have advantages in both 
these areas and comparisons of CMR and ultrasound for 
accuracy and reproducibility favour CMR [164]. In addi-
tion to measuring brachial dilation, CMR can also meas-
ure flow changes directly in response to the standard 
stimuli [165, 166] and has been used to assess residual 
signs of vascular damage after repair of aortic coarctation 
[167]. Vascular reactivity can also be measured in lower 
extremity arteries and, more so than in the forearm arter-
ies, has been shown to be progressively reduced with an 
increase in cardiovascular risk factors [168].
Venous system
The main indications for imaging the central veins are 
assessment of suspected anatomical variants and follow-
up of patients with CHD [169], mapping of pulmonary 
venous anatomy [170], vena cava superior syndrome 
[171] as well as assessment of the central veins prior to 
creation of upper extremity vascular access in patients 
with renal dysfunction [172]. CMR venography is also 
increasingly used to assess the peripheral venous system 
in patients with venous compression syndromes [173], 
venous anomalies [174], and suspected or known deep 
venous thrombosis of both the upper [175] and lower 
extremities [176].
Both CE and non-contrast CMRA techniques can be 
used for depiction of the venous system. For imaging of 
chest veins non contrast cardiac triggered and respira-
tory navigator-gated bSSFP techniques can provide excel-
lent image quality in short imaging times [177] and is 
often sufficient to answer the clinical question. CE-CMR 
venography can be performed with both extracellular 
as well as blood pool contrast agents. The approximate 
intravascular half-life of extracellular chelates is around 
60–120  s [178]. Thus, when a conventional extracellu-
lar contrast agent is used, rapid leakage of the contrast 
agent into the interstitial space will reduce enhancement 
of both the arteries and the veins shortly after injection. 
In order to obtain good quality images of the venous sys-
tem it is therefore mandatory to initiate the acquisition 
immediately after the first pass of the contrast agent. An 
alternative strategy is to use the blood pool agent feru-
moxytol, which has a much longer intravascular half-
life, and thereby facilitates ultra-high spatial resolution 
depiction of both the arterial as well as the venous sys-
tems with voxel sizes about one order of magnitude 
smaller compared to conventional CMR vascular imaging 
techniques [179]. This contrast agent has been shown to 
be of high value in patients with CHD [180], imaging of 
central [181], abdominal [182] and peripheral veins [183].
Coronary artery disease
Coronary artery disease (CAD) spans a broad range of 
acquired and congenital coronary artery abnormalities. 
The vast majority of events such as myocardial infarction 
(MI) result from atherosclerosis. CAD may be further 
classified as ‘macrovascular’—involving the epicardial 
segments of the coronary artery tree—or ‘microvascu-
lar’ where vasomotor, neurohormonal and other factors 
affect the coronary microcirculation. CMR has proven 
utility in addressing most aspects of CAD, illuminating 
mechanism of disease and guiding the selection of thera-
peutic strategies (Table 3).
Acute coronary syndromes
Patients with acute coronary syndrome (ACS) have 
myocardial ischemia or injury resulting from disrup-
tion to coronary blood flow. Assessment of a standard 
12-lead electrocardiogram (ECG) at presentation yields 
2 broad categories of ACS: ST-segment elevation myo-
cardial infarction (STEMI) and non-ST elevation events 
(NSTEMI). Classically, STEMI results from complete 
thrombotic occlusion of a coronary artery segment, 
whereas NSTEMI may represent subtotal occlusive or 
erosive CAD. Recognition of STEMI mandates rapid, 
uniform deployment of community-to-catheterization 
laboratory evaluation and management aimed at reca-
nalization of the occluded coronary artery. No modality 
including CMR has shown compelling utility to support 
slowing down established pathways by adding imag-
ing between presentation and coronary intervention. 
After invasive coronary angiography, however, CMR 
with its workhorse imaging technique of late gadolinium 
enhancement (LGE) affords in vivo visualization of myo-
cardial injury, and hypointense regions within infarct 
scar indicate microvascular obstruction (MO). CMR 
may inform post-STEMI care when complicated by heart 
Table 3 Indications for CMR in coronary artery disease
Indication Class
1. Acute coronary syndromes I
2. Chronic coronary artery disease I
3. Myocardial infarction with non-obstructive coronary arteries 
(MINOCA)
I
4. Coronary artery anomalies II
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failure, arrhythmias, or LV dysfunction. The transmural 
extent of myocardial damage by LGE is inversely related 
to the likelihood of functional recovery, with even worse 
prognosis conferred with the presence of MO [184]. 
T2-weighted imaging combined with LGE has been used 
to detail the extent of myocardium that has been salvaged 
after revascularization in patients with STEMI [185]. 
Fortunately, mechanical complications post-STEMI such 
as papillary muscle rupture, free wall rupture and post-
infarct ventricular septal defect have diminished in the 
era of rapid catheter-based reperfusion. However, rep-
erfusion myocardial injury and intramyocardial hem-
orrhage still occur and may contribute to residual risk 
[186]. The comprehensive nature of CMR can fully char-
acterize the jeopardized region in aborted STEMI, while 
precisely assessing the complications such as RV infarc-
tion, post MI pericarditis, and thrombus formation [187–
189]. Contemporary mapping of myocardial T1, T2 and 
T2* values along with traditional LGE imaging affords 
detailed characterization of cardiac muscle post-STEMI, 
affording insights into mechanisms of adverse remod-
eling and other downstream complications [190].
These techniques can be used to test novel approaches 
to preserve myocardium in STEMI, such as optimal tim-
ing of stent placement in patients undergoing aspira-
tion thrombectomy [191]. Incorporating CMR’s precise 
myocardial biomarkers has accelerated the evaluation 
of a number of complementary therapeutic approaches. 
For instance, Bulluck and colleagues [192] evaluated 
treatment with a mineralocorticoid receptor antagonist 
drug intravenously at the time of primary percutane-
ous coronary intervention (PCI) and continued orally 
for 10 weeks after PCI; CMR was performed in the first 
week and again after 3 months. While mineralocorticoid 
receptor antagonist therapy did not reduce infarct size, 
LV remodeling did improve. Such CMR-enabled studies 
advance the evidence needed to improve post-STEMI 
outcomes.
NSTEMI patients are more heterogeneous compared 
to STEMI not only in ECG findings but also in time 
course of presentation and revascularization. Impor-
tantly, NSTEMI comprise the vast majority of all ACS 
and may represent a greater opportunity for CMR to 
guide management. For instance, T2 imaging prior to 
invasive angiography in patients with NSTEMI has been 
shown to delineate myocardium at risk of irreversible 
injury, predicting both presence of CAD requiring revas-
cularization as well as greater risk of adverse outcomes 
[193]. Recent trials have confirmed no advantage of 
early (within a few hours) vs. usual (within 72 h) timing 
of invasive coronary angiography (ICA) in the aggregate 
NSTEMI population lacking high risk features [194]. 
These data encourage feasibility of further trials that 
incorporate CMR into the evaluation of patients with 
NSTEMI, particularly as novel strategies emerge to pro-
tect myocardium from both ischemic as well as reperfu-
sion injury. Incorporating CMR after angiography and 
randomization to either thrombectomy or standard PCI 
in NSTEMI, Thiele and colleagues [195] found that com-
bining aspiration thrombectomy with PCI in NSTEMI 
with a thrombus-containing lesion did not reduce MO.
Chronic coronary artery disease
Symptomatic patients with known or suspected stable 
CAD may require evidence that symptoms are a result of 
CAD. Delineation of ischemic myocardium with stress 
myocardial perfusion imaging can guide coronary artery 
revascularization, targeting ischemic segments towards 
relief of symptoms (Fig.  6). Several head-to-head tri-
als now endorse stress  CMR with vasodilator perfusion 
as a more accurate modality in evaluating the sympto-
matic CAD patient [196, 197], with better utilization of 
costly resources like ICA [198]. A subsequent substudy of 
CE-MARC indicated greater accuracy in left main stem 
or equivalent CAD, recognizing grave consequences in 
missing such disease [199] and the MR-INFORM trial 
puts stress CMR on equal footing as assessment of what 
many deem the gold standard for CAD severity – inva-
sive fractional flow reserve [200].
In an era of more complex questions regarding native 
coronary artery or bypass graft anatomy amidst scarred 
vs viable myocardium, CMR has distinct advantages over 
other modalities. While single photon emission tomog-
raphy (SPECT) may infer the presence of infarct scar in 
patients with ‘fixed defects’ e.g. reduced tracer uptake on 
both rest and stress perfusion images, having both LGE 
and perfusion imaging techniques allows CMR to better 
distinguish scar from hibernating myocardium [201].
For individuals presenting in the acute setting with 
symptoms of intermediate CAD likelihood, stress perfu-
sion CMR accurately identifies disease and safely facili-
tates discharge in patients with normal results, at lower 
cost when compared to standard inpatient evaluation 
with ICA [202].
The International Study of Comparative Health Effec-
tiveness with Medical and Invasive Approaches, or 
ISCHEMIA trial, asked—how does routine invasive ther-
apy improve outcomes compare to optimal medical ther-
apy in patients with stable CAD and moderate to severe 
myocardial ischemia on noninvasive stress testing? While 
analysis from the small subgroup of subjects whose test-
ing included stress CMR is underway, the overall trial 
results from over 5,000 patients randomized across 320 
centers in 37 countries followed for a little over 3  years 
are relevant to today’s CMR practice. With a cohort of 
over three-fourths male patients with a significant burden 
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of diabetes (41.8%), prior MI (19.2%) and preserved LV 
ejection fraction (LVEF) (median 60%), the primary out-
come of cardiovascular death, MI, resuscitated cardiac 
arrest, or hospitalization for unstable angina or heart 
failure was similar among routine invasive (13.3%) and 
medical therapy (15.5%) groups (p = 0.34). These results 
endorse use of an accurate, cost-effective and noninvasive 
modality such as stress CMR in such patients in place of 
invasive evaluation.
Myocardial infarction with non‑obstructive coronary 
arteries (MINOCA)
Myocardium may suffer infarction from causes other 
than obstructive CAD such as plaque erosion, spon-
taneous coronary artery dissection, coronary artery 
vasospasm, and coronary artery embolization. CMR 
is typically called upon after ICA has not provided a 
definitive anatomic abnormality, and when distinction 
of MI from myocarditis may be difficult by symptoms 
such as chest pain with biomarker evidence of myo-
cardial injury. Occasionally, the angiogram is reviewed 
after CMR shows the classic signature of MI—subendo-
cardial pattern of damage by LGE—and subtle invasive 
coronary angiography findings of erosive plaque or dis-
section are found retrospectively. In this setting, LGE 
unequivocally identifies the downstream myocardial 
damage as ischemic vs. inflammatory (i.e. subendocar-
dial vs. epicardial injury) [203] making CMR central per 
recent guidelines from a broad international writing 
group in the very definition of MI [204].
Dastidar and colleagues added significant evidence 
supporting CMR’s utility in both diagnosis and prog-
nostic assessment in patients with myocardial infarc-
tion with non-obstructive coronary arteries (MINOCA) 
[205]. CMR—including cine, T2, and LGE imaging—
was performed in 388 patients approximately 1 month 
after emergent or urgent invasive coronary angiography 
and showed nonobstructive CAD in the face of evident 
myocardial damage by elevation in blood troponin-T 
levels. The diagnosis of MINOCA was further refined 
by CMR as myocarditis in 25%, myocardial infarction in 
25%, and cardiomyopathy in 25%. With 5.7% of patients 
suffering mortality after an average of 3.5  years, CMR 
diagnosis of cardiomyopathy combined with ECG pres-
ence of ST elevation were the only significant predic-
tors of mortality in multivariable regression analysis. 
Importantly, such a diagnosis would be missed by 
modalities without CMR’s ability to identify myocar-
dial disease, and consideration of appropriate treat-
ment to improve outcomes in cardiomyopathy could be 
neglected. Such findings underscore the essential role 
of CMR in MINOCA.
Fig. 6 A 75 year-old male with hypertension and hyperlipidemia reported exertional dyspnea during rehabilitation post-stroke. Transthoracic 
echocardiography (TTE) showed mild left ventricular (LV) systolic dysfunction, and he had difficulty walking. Given concern for myocardial ischemia, 
he was referred for CMR with stress. Late gadolinium enhancement (LGE) demonstrates a small subendocardial infarct in the basal inferior wall, 
while myocardial perfusion acquired during adenosine infusion (stress) shows extensive perfusion abnormality that mostly resolves on resting 
perfusion imaging. Cine CMR demonstrates mild segmental LV dysfunction. These findings prompted invasive coronary angiography that showed 
high-grade multivessel coronary artery disease (CAD); post-revascularization, functional capacity improved
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Coronary anomalies
A contemporary understanding of coronary artery devel-
opment sheds light on the range of anomalies that may 
result including anomalous connection, intrinsic abnor-
mality such as non-atherosclerotic ectasia or ostial 
atresia, and anomalous myocardial/coronary artery inter-
action [206]. While infrequently detected in adults under-
going invasive coronary angiography, coronary anomalies 
contribute to sudden death in young individuals, espe-
cially athletes, and may also occur in conjunction with 
other congenital abnormalities. The volumetric nature 
of CMR makes it ideal in visualizing the proximal course 
that may not be apparent by two-dimensional projection 
X-ray angiography. CMRA easily identifies inter-arterial 
(traveling between the ascending aorta and pulmonary 
artery) vs. retroaortic coronary anomalies, with greater 
concern regarding sudden death risk in the former [57]. 
While other modalities such as coronary CTA offer more 
reliable imaging of the mid and distal segments of the 
coronary artery tree, such distinction of the proximal 
anatomy is well within reach of CMR without requiring 
ionizing radiation. Navigator-triggered noncontrast coro-
nary  CMRA further removes the requirement for exog-
enous iodinated contrast to image the proximal course of 
the coronary arteries [207].
Ongoing and future clinical trials will hopefully illu-
minate novel CAD treatment approaches informed by 
CMR, particularly with mechanistically relevant end-
points to test efficacy.
Kawasaki Disease
Kawasaki Disease is the prototypical systemic vasculitis 
that affects the coronary arteries. A disease with pedi-
atric predilection, Kawasaki Disease typically presents 
with persistent fever and rash. Its potential for inflam-
mation and aneurysm formation of the coronary arteries 
and ensuing myocardial damage typically mandates car-
diovascular assessment, both acutely as well as in conva-
lescence. CMR is ideal for comprehensive coronary and 
myocardial assessment in patients with Kawasaki Dis-
ease. Mavrogeni and colleagues offer a cogent summary 
of recommended CMR-based assessment during acute 
and chronic phases of the disease well-suited for tech-
niques like coronary CMRA, functional assessment, per-
fusion with or without stress, and LGE imaging [208]. A 
recent quantitative CMR study, including circumferential 
strain measurements, showed changes like fibrotic myo-
cardial remodeling beyond infarcted tissue in 19, mostly 
male, children with Kawasaki Disease [209].
These findings in a relatively rare disease are urgently 
relevant as the world struggles to respond to a Kawasaki 
Disease-like disease in children linked to the COVID-19 
pandemic caused by severe acute respiratory syndrome 
coronary virus 2 (SARS-CoV-2) [210]. Systematic CMR 
studies are needed in children and convalescent adults 
to understand the long-term sequelae related to this 
increasingly recognized complication of COVID-19.
Myocarditis and other cardiomyopathies
The cardiomyopathies are commonly understood as pri-
mary myocardial diseases, that are not caused by CAD, 
hypertension, valvular or CHD [211]. Importantly, cardi-
omyopathies are often characterized by tissue abnormali-
ties that reflect chronic injury, infiltration, or abnormal 
storage of molecules [211]. These pathologies lead to sig-
nal intensity changes in CMR images before or after con-
trast agent injection. Their signal behaviours and regional 
distribution patterns often represent important com-
plementary diagnostic information [212]. Yet, often the 
findings obtained by CMR alone is sufficient for estab-
lishing a diagnosis. Over the recent years, CMR has been 
increasingly accepted as a critically important tool in car-
diovascular disease management [213] (Table 4).
CMR is widely accepted as the non-invasive gold 
standard for quantifying biventricular volumes, myo-
cardial mass as well as regional/global  systolic function 
[214]. LV function can be assessed using simplified CMR 
approaches such as biplanar long axis views [215] or rota-
tional long axis views [216], yet typically short axis stacks 
of both ventricles are applied [217, 218]. There is consen-
sus about the methods of the quantitative assessment of 
the heart in CMR images [219]. Normal values have been 
published for the LV [218, 220] and RV [221].
CMR is the most appropriate non-invasive method 
to assess tissue characteristics in vivo. The fundamental 
Table 4 Indications for CMR of cardiomyopathies
Indication Class
1. Dilated cardiomyopathy I
2. Myocarditis I
3. Hypertrophic cardiomyopathy I
4. Arrhythmogenic cardiomyopathy I
5. Cardiac amyloidosis I
6. Myocardial iron overload I
7. Left-ventricular noncompaction I
8. Fabry’s disease I
9. Cardiac sarcoidosis I
10. Stress-induced (Takotsubo) cardiomyopathy I
11. Endomyocardial fibrosis I
12. Restrictive cardiomyopathy II
13. Chemotherapy induced CMP II
14. Athlete’s heart II
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contrast-generating principle of CMR is rooted in the 
close relationship between the magnetic properties of 
tissue and its molecular composition. These predict the 
results of myocardial mapping and affect the signal inten-
sity in standard CMR images. Standard CMR techniques 
include contrast-enhanced T1-weighted CMR after iv 
administration of contrast agents, typically GBCAs. 
These techniques have been successfully applied to visu-
alize necrosis, scar, infiltration, inflammation, or intra-
ventricular thrombi, while edema-sensitive T2-weighted 
CMR images can help identify acute injury [222]. T2*-
weighted imaging have proven useful in the detection of 
myocardial hemorrhage [223] and thrombi [224]. Myo-
cardial mapping allows for directly measuring the change 
of magnetic properties as expressed by the magnetic 
relaxation times native T1, T2, T2*, and the extracellular 
volume (ECV) derived from post contrast T1 [225].
Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is characterized by ven-
tricular dilatation, global systolic dysfunction and often 
accompanied by global myocardial fibrosis. CMR can 
accurately quantify volumes as well as regional and global 
LV function including wall thickening, and wall stress 
[226]. RV volumes, morphology, and function can usu-
ally be better assessed by CMR than with TTE [227]. In 
patients with DCM, LGE imaging can visualize regional 
fibrosis that allows for discriminating non-ischemic 
DCM from ischemic CMP by the invariably predominant 
subendocardial involvement [228]. An intramural layer of 
bright signal intensity, typically involving the basal anter-
oseptal segment, also known as “midwall stripe”, is found 
in about one quarter of patients with DCM patients and 
is a predictor of sudden death and ventricular arrhythmia 
[229]. This sign, albeit not specific for non-ischemic car-
diomyopathy (CMP) may therefore be useful in the deci-
sion-making related to the implantation of implantable 
cardioverter-defibrillators. LGE imaging is also useful in 
the follow-up of patients with DCM. Myocardial map-
ping appears useful in patients with DCM [230], possible 
as an early marker [231].
Myocarditis
CMR is regarded as the most useful non-invasive tool to 
assess for  myocarditis [232]. It adds diagnostic value to 
a standard clinical follow-up [233] and its use increases 
the observed incidence of myocarditis [234]. However, 
it remains important to keep in mind that myocardial 
inflammation is not specific to viral myocarditis but also 
occurs in other acute myocardial diseases such as acute 
MI, acute cardiotoxicity, immune checkpoint inhibitor 
myocarditis or stress-induced Takotsubo cardiomyo-
pathy. A recent expert consensus document provides 
guidance on the CMR techniques and their role in non-
ischemic myocardial inflammation [235]. Although ven-
tricular volumes, morphology and function often remain 
normal and thus their quantitative assessment is less 
important than in other non-ischemic cardiomyopa-
thies, CMR may be useful by accurately quantifying these 
parameters at acute presentation and during follow-up.
The diagnostic targets of CMR include edema and an 
increased extracellular space caused by necrosis or scar. 
The recently updated Lake Louise Criteria for CMR in 
Non-Ischemic Myocardial Inflammation recommend to 
assess them using T1-based and T2-based markers that 
detect myocardial edema and myocardial injury [235]. 
Figure 7 shows an overview of the criteria.
Increased signal intensity in T2-weighted imaging 
reflects inflammation-related myocardial edema [236, 
237]. Patients with myocarditis typically show a regional 
or global signal intensity increase [237]. Edema may also 
be found in patients with DCM [238]. Irreversible myo-
cardial injury can visualized in LGE images as areas with 
increased signal intensity with a non-ischemic regional 
distribution pattern [237, 239], with good agreement to 
histopathology [240]. LGE however has a limited sen-
sitivity to detect myocarditis and is not specific to the 
acuity of the disease [235, 241]. The updated diagnostic 
criteria in suspected non-ischemic myocardial inflamma-
tion include (a) evidence for myocardial edema as shown 
by either an increased signal intensity in T2-weighted 
CMR images or an increased T2, and (b) evidence for 
myocardial injury as shown by either an increased myo-
cardial T1, an increased myocardial ECV, or LGE in a 
non-ischemic regional distribution pattern [235]. Myo-
carditis is typically benign and myocardial edema dis-
appears within weeks [241], whereas irreversible injury 
results in scars with persisting LGE.
Hypertrophic cardiomyopathy
The hallmarks of hypertrophic cardiomyopathy (HCM) 
include an inadequate, mostly asymmetric increase of 
wall thickness and typically increased LV mass, associ-
ated with structural abnormalities, regional fibrosis, and 
LV outflow tract (LVOT) obstruction. All these markers 
can be quantitatively assessed by CMR. Myocardial wall 
thickness can be measured with more confidence than 
with TTE [242]. Of note, global LV mass may be normal, 
even in cases with marked regional hypertrophy [243]. 
Myocardial crypts have been associated with HCM [244], 
even in the absence of LV hypertrophy [245]. An overlap 
with the phenotype of LV non-compaction (LVNC)  is 
being discussed. Abnormal global longitudinal strain is a 
marker for an impaired prognosis [246].
In HCM, the diagnostic workup can be significantly 
improved by CMR tissue characterization. Areas of 
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marked hypertrophy often show regional fibrosis as focal 
areas with high signal intensity in LGE images [247, 248]. 
Furthermore, they occur at the insertion areas of the 
RV, likely due to increased mechanical stress in combi-
nation with relative coronary insufficiency in hypertro-
phied regions. LGE in HCM is associated with the risk 
for heart failure [249] and sudden cardiac death [250]. 
More definitive data are expected soon from the 3500 
patient Hypertrophic Cardiomyopathy Registry (HCMR) 
trial [251]. Edema associated with HCM can be visual-
ized by T2-weighted sequences, often co-localized with 
LV hypertrophy and irreversible injury [252].
Another diagnostic target in the clinical phenotyping 
of HCM is the presence and hemodynamic relevance of 
LVOT obstruction. This can be assessed by planimet-
ric evaluation of the LVOT area [253], a parameter that 
appears to be more robust than the pressure gradient 
derived from 2D or 4D flow imaging [254]. In-plane flow 
imaging can be helpful to localise the peak LVOT veloc-
ity, but velocity quantitation can be difficult as the accu-
racy of flow mapping is often reduced in higher degrees 
of LVOT obstruction, due to the very narrow, turbulent 
jets with high acceleration.
CMR is suitable for monitoring functional and mor-
phological changes after therapeutic interventions [253]. 
More recently, myocardial relaxation time mapping has 
also been applied to HCM [255] and helps improving our 
understanding of the interaction between morphology 
and function with tissue characteristics [256]. It is clini-
cally important to distinguish pathological LV hypertro-
phy from athlete’s heart. This can be achieved by CMR 
using functional indices [257] or, as recently shown by the 
verification of a normal or even decreased proportional 
amount of extracellular space. Pathological hypertrophy 
is associated with an increased ECV, while athlete’s heart 
is not [258].
Arrhythmogenic cardiomyopathy
Arrhythmogenic cardiomyopathy is a cause of sudden 
death, especially in young people. As it is associated with 
morphological and functional abnormalities of the RV, 
CMR is a preferred tool for adding diagnostic informa-
tion to other known criteria derived from family history, 
ECG, and biopsies [259–261]. While the assessment 
of RV free wall fat is not used anymore, morphological 
and functional abnormalities serve as markers [262]. The 
original ESC Task Force criteria from 1994 [263] have 
been modified in 2010 to increase sensitivity [264]. Sub-
sequent studies however have shown that sensitivity may 
be even lower, possibly because microaneurysms in the 
Fig. 7 CMR criteria for non-ischemic myocardial inflammation (“Lake Louise Criteria”)
Page 18 of 37Leiner et al. J Cardiovasc Magn Reson           (2020) 22:76 
absence of RV dilatation have been removed as a marker 
[265]. Other abnormalities observable by CMR include 
trabecular hypertrophy and a irregular dilatation with 
trabecular hypertrophy of the basal RV wall (“accordion 
sign”) [262].
The assessment of the RV is often complicated by large 
interindividual differences of the anatomy, its irregular 
shape and difficulties in visualizing the connected valves 
by standard views. As arrhythmogenic cardiomyopathy 
is also associated with fibro-fatty or fatty degeneration of 
the myocardium, many studies have attempted to estab-
lish new diagnostic criteria based on tissue alone. While 
areas with bright signal intensity have been described in 
the RV or LV free walls, RV wall tissue characterization 
has been notoriously difficult because of the thinness 
of the RV wall and the resulting susceptibility to partial 
volume effects, that render tissue characterization tech-
niques unreliable.
Cardiac amyloidosis
In patients with amyloidosis, cardiac involvement typi-
cally predicts their outcome. The main purpose of CMR 
therefore is the exclusion or confirmation of cardiac amy-
loid. While cine images are important to assess for the 
typical combination of concentric LV hypertrophy with 
reduced compliance and restriction, often combined with 
atrial dilatation and thickening of the valves and the atrial 
wall, the most important contribution of CMR is based 
on its ability to demonstrate tissue characteristics. The 
deposition of amyloid protein in the myocardium results 
in a marked increase of native myocardial T1 [266] and 
to a rapid and strong uptake of gadolinium with a typi-
cal rapid clearance of the blood from the contrast agent 
[267]. Because the increase of native T1 is extensive, 
amyloid can in many patients be demonstrated by myo-
cardial mapping, without the use of a GBCA [225]. Of 
the mapping variables, the ECV has been shown to most 
closely mirror the amyloid burden and the response to 
treatment, probably because T1 and T2 effects vary with 
variable presence of inflammation in this condition.
Myocardial iron overload
Suspected myocardial iron deposition in patients under-
going repeated transfusions has become one of the most 
important applications of CMR, especially in geographi-
cal areas with a high incidence of thalassaemia, although 
this disease is now present worldwide due to immigra-
tion. As heart failure is the most frequent cause of death 
in patients with untreated iron overload, CMR can play a 
critical role in managing such patients. Because iron acts 
as a paramagnetic agent, its presence can be detected by 
its marked shortening effect on myocardial T2*. Since 
the introduction of this technique [268], the approach 
has been shown to be clinically very useful [269] and has 
greatly reduced cardiac mortality by ensuring early heart-
tailored iron chelation treatment is started in patients 
who have been shown to be at high risk (those with 
T2* < 10  ms) [270]. CMR is directed toward the detec-
tion of myocardial iron deposits [271]. The T2* CMR 
technique has been validated in randomised controlled 
trials and is calibrated against human myocardium [272]. 
Recently, native T1 has been proposed as a marker of car-
diac iron [273], but remains controversial because of lack 
of validation against outcomes and human tissue [274].
Left‑ventricular noncompaction
Left-ventricular noncompaction (LVNC) cardiomyopa-
thy is characterized by LV dilatation, hypokinesis, and 
an abnormally high proportion of trabecular, non-com-
pacted myocardium in combination with a thin com-
pact wall. Initially described by TTE [275], the disease is 
associated with sudden cardiac death, yet is insufficiently 
understood [276, 277]. A genetic and phenotypic overlap 
with HCM is likely [278]. Generally, a wall thickness ratio 
of noncompacted over compacted wall of 2.3 or higher 
was proposed to verify LVNC [279], yet the specificity 
of non-compacted LV myocardium for this disease has 
been questioned [280, 281]. More recently, a cutoff of 3 
was proposed [282]. Other studies proposed a cutoff of 
20% of trabecular proportion of the entire LV myocardial 
mass [283] or a 35% proportion of non-compacted vol-
ume of 35% of the LV volume [284]. LGE was not found 
to be a strong diagnostic marker [285] although a recent 
meta-analysis found that patients with LVNC but without 
LGE have a better prognosis than those with LGE. When 
LGE is negative and global systolic function is preserved, 
no hard cardiac events are to be expected [286]. While a 
clearly abnormal amount of trabeculation in combination 
with a thin, hypocontractile wall allows for establishing 
the diagnosis, care should be taken not to overcall LVNC 
[287].
Anderson‑Fabry disease
Anderson-Fabry disease is caused by an enzyme defect 
leading to the accumulation of sphingolipids. Because 
the morphological appearance in myocardial involve-
ment is indistinguishable from other forms of symmetric 
hypertrophy, the ability of CMR to identify sphingolipid 
storage in the myocardium has become a key diagnostic 
tool [288, 289]. Lipids lead to a decrease of native T1 and 
thus, concentric LV hypertrophy with a globally reduced 
T1 allows for the diagnosis of Anderson-Fabry Disease 
[225, 290]. LGE images can demonstrate layers of LGE, 
typically in the lateral wall [291]. Recently, evidence was 
provided that Anderson-Fabry Disease can present with 
edematous inflammation that can be demonstrated 
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by increased T2 values [292]. Figure  8 shows a case 
of Anderson-Fabry disease with basal lateral LGE, a 
decreased T1 and an increased T2.
Cardiac sarcoidosis
In patients with pulmonary or extracardiac  sarcoido-
sis, CMR should be used to verify or exclude myocardial 
infiltration and associated inflammation [293–295] as 
cardiac involvement is a frequent cause of death in this 
population [296]. Next to LV dilatation and often global 
systolic dysfunction, the patterns of the regional distri-
bution of myocardial lesions varies substantially, even in 
the same individual and may be intramural, transmural, 
subendocardial or subepicardial (Fig.  9) [254, 297, 298]. 
Edema is often present and identifiable on T2-weighted 
images [254, 299].
Stress‑induced (Takotsubo) cardiomyopathy
Stress-induced cardiomyopathy, also known as Takot-
subo cardiomyopathy, is characterized by a reversible, 
extensive systolic wall motion abnormality, typically pri-
marily involving the mid and apical LV [300, 301]. As with 
other imaging techniques, CMR can visualize systolic 
“ballooning” of the LV. On a tissue level, the hallmark of 
Fig. 8 CMR in a patient with Anderson-Fabry Disease and associated myocardial inflammation. Upper row: LGE images showing inferolateral 
subepicardial LGE (arrowheads). Middle row: Native T1 maps showing a global decrease of native T1, specifically in the inferolateral wall (arrows). 
Lower row: T2 maps with increased myocardial T2, including the inferolateral wall, co-located with the areas that showed a low T1 (arrows)
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stress-induced cardiomyopathy however is transmural 
extensive edema [302]. LGE is rarely observed. Results of 
an international multi-center trial indicate that the CMR 
findings are consistent with acute inflammation (likely 
induced by catecholamines) and that the combination 
of the typical wall motion abnormality with extensive 
edema in the absence of LGE may allow for establishing 
the diagnosis [303, 304].
Endomyocardial fibrosis
Endomyocardial fibrosis leads to a mainly apical concen-
tric wall thickening, caused by extensive subendocardial 
fibrosis, frequently associated with an apical intraven-
tricular thrombus. CMR is used to assess for ventricular 
volumes (typically small), and systolic dysfunction. As a 
more specific finding, endomyocardial fibrosis can be 
verified by LGE images [305, 306]. This pattern has also 
been described in patients with Churg-Strauss Syndrome 
[307].
Restrictive cardiomyopathy
In patients with suspected myocardial  restriction, CMR 
assessment helps in verifying the diagnosis by demon-
strating small ventricles in combination with enlarged 
atria [308–311]. Furthermore, CMR allows for exclusion 
of  constrictive pericarditis by demonstration absence  of 
pericardial thickening [312] or by the absence of sep-
tal flattening during deep inspiration (real-time cine 
CMR sequences) [313]. Data however are scarce as this is 
a relatively rare entity.
Pericardial disease
The pericardium—a virtual, sub-atmospheric space under 
normal circumstances—can be the location and cause of 
significant cardiac morbidity and mortality. Standard car-
diac imaging modalities such as TTE, not infrequently 
fail to adequately investigate this part of the heart. Other 
imaging techniques such as CT provide an excellent 
morphologic view on the pericardium but are limited to 
depict the hemodynamic impact on pericardial disease 
on the heart. CMR has evolved to one of the preferred 
modalities for pericardial imaging [314, 315]. Using a 
series of CMR sequences, a combined morphologic-
functional view on the heart and pericardium is achieved, 
providing adequate information with regard to the condi-
tion of pericardium, hemodynamic consequences on the 
heart and the presence of concomitant or superimposed 
myocardial/valvular disease [315] (Table  5). Morpho-
logic sequences (e.g. spin-echo based sequences) allow 
detailed description of pericardial anatomy and its rela-
tion with the heart and surrounding anatomic structures. 
Pericardial tissue characterization—pericardial edema/
Fig. 9 LGE images in a patient with pulmonary sarcoidosis and extensive cardiac involvement. There are several focal non-subendocardial 
based LGE areas with infiltration (arrows) in a variable pattern of transmural distribution
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inflammation/fibrosis—is achieved using a combination 
of non-contrast and CE sequences. It should be men-
tioned that for identification of pericardial calcium, CT is 
the best imaging modality [316]. bSSFP cine CMR allows 
to evaluate hemodynamic consequences, i.e. cardiac tam-
ponade and constriction. In particular real-time bSSFP 
cine CMR during free breathing is able to depict patho-
logic ventricular coupling in patients with constrictive 
pericarditis [317]. Finally, phase-encoded cine CMR is 
of interest to study the cardiac inflow patterns, and thus 
to obtain information with regard to diastolic function 
[318].
Pericardial effusions
Together with CT, CMR is likely the preferred modality 
to diagnose and to differentiate pericardial effusion. As 
CMR is not limited as echocardiography by the need of 
an adequate acoustic window, the entire pericardium can 
be satisfactorily investigated allowing to depict small or 
loculated effusions or to describe complex configurations 
[314, 315]. Typically, pericardial effusion yields high sig-
nal intensity at bSSFP cine CMR, allowing to depict for 
example fibrinous strands [315]. Although TTE is the 
first-line imaging modality in patients with cardiac tam-
ponade, right atrial/ventricular collapse can be shown 
at bSSFP cine CMR as well, for example in patients with 
chronic pericardial effusions. As pericardial effusion 
frequently occurs in the setting of inflammatory peri-
carditis, and rarely in constrictive pericarditis (‘effusive–
constrictive’ forms), CMR is highly useful to differentiate 
simple effusions from pericarditis-related effusions.
Pericardial inflammation
Inflammatory pericarditis can be isolated or part of sys-
temic disease. TTE diagnosis relies on the depiction of 
pericardial effusion. However, many patients have no (the 
so-called “dry pericarditis”) or only physiologic amounts 
of pericardial effusion [319]. As pericarditis is histo-
logically characterized by thickening, edema, increased 
vascularity, and inflammation of the pericardial layers, 
the alterations can be used to depict pericardial inflam-
mation at CMR [320]. Edema of the pericardial layers 
yields high-signal at T2-weighted spin-echo sequences. 
Also, at LGE CMR imaging, pericardial inflammation is 
characterized by strong pericardial enhancement [321]. 
In cases of effusive-inflammatory pericarditis, LGE CMR 
imaging allows to differentiate the inflammatory compo-
nent (‘bright’) from the effusive component (‘dark’). CMR 
allows as well to depict associated inflammatory myocar-
ditis. In patients with recent MI, CMR is well suited to 
depict epistenocardiac pericarditis [322].
Pericardial constriction
Patients with pericardial inflammation, even relapsing 
forms, rarely evolve towards an end-stage constric-
tive pericarditis [314, 315]. Histologically, the con-
strictive pericardium consists of collagen-rich fibrous 
pericardium often with several foci of calcifications. 
This non-compliant pericardium constricts the heart 
and may cause diastolic heart failure [323]. Imaging 
involves description of the pericardium, and on the 
consequences of the constriction on cardiac morphol-
ogy and function [314, 315]. Although traditionally 
regarded as a thick pericardium, thickness as such has 
a limited role in defining constrictive pericardium. It 
has been shown that evolution from an inflammatory 
towards a constrictive pericardium causes a thinning of 
the abnormally thickened pericardium, likely explain-
ing why at histology a substantial number of patients 
with constrictive pericarditis presents with mild peri-
cardial thickening (Figs.  10, 11) [324–326]. End-stage 
constrictive pericardium typically presents with low-
signal intensity at T1-weighed spin-echo CMR often 
with irregular borders. In contrast to pericardial 
inflammation, T2-weighted spin-echo CMR shows lack 
of pericardial edema and LGE CMR shows no or lim-
ited contrast enhancement [321]. In patients with clini-
cally suspected constrictive pericarditis, the degree of 
enhancement can be used to predict reversibility and 
to determine patients who still may benefit of anti-
inflammatory treatment [324, 325]. As the pericardium 
at the atrioventricular sulcus and right side of the heart 
are most frequently and extensively affected, external 
compression of the heart at these places is most com-
mon. As a consequence, the right atrium and inferior 
vena cava are dilated, and patients often present pleural 
effusion [314]. As the morphologic features in constric-
tive pericarditis may be not impressive, assessment of 
the hemodynamic consequences is crucial, which can 
be achieved looking at the ventricular coupling. Con-
strictive pericarditis patients show pronounced inspir-
atory flattening and/or inversion of the ventricular 
septum, while during expiration the opposite phenom-
enon occurs with increased right-sided septal motion. 
A simple and elegant way to evaluate ventricular cou-
pling is the use of real-time free breathing bSSFP cine 
CMR while asking the patient to deep breathe in and 
Table 5 Indications for CMR in pericardial disease
Indication Class
1. Pericardial effusions III
2. Pericardial inflammation I
3. Pericardial constriction I
4. Congenital anomalies of the pericardium I
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out [317]. Also, phase-contrast cine CMR with real-
time imaging can be used showing abnormal variation 
of inflow velocities [318]. Line tagging, with the tag 
lines perpendicularly positioned on the pericardium 
may be of interest to assess fibrotic adhesion of the 
pericardial layers as well as to judge pericardial motion 
with respect to the underlying myocardial deforma-
tion across the cardiac cycle. In patients with constric-
tive pericarditis, the calcifications are not necessarily 
confined to the pericardium but may extent into the 
underlying myocardium, affecting regional and if pro-
nounced also global systolic function [316].
Congenital abnormalities of the pericardium
Pericardial cyst is the most common pericardial con-
genital abnormality and is usually an incidental finding 
in asymptomatic patients [314, 315]. As the location and 
presentation are typical, the diagnosis is usually straight-
forward. Pericardial cysts are typically paracardiac in 
location and present low signal intensity at T1-weighted 
Fig. 10 62-year-old woman with clinical presentation of Dressler’s syndrome following mitral and tricuspid valve replacement. Axial T1-weighted 
FSE imaging shows mildly thickening pericardium (a, black arrows). Short-axis T2-weighted fast spin echo imaging shows diffuse hyperintense 
appearance of the pericardium (b, white arrows). Late gadolinium enhancement imaging in cardiac short-axis shows diffuse strong pericardial 
enhancement (c, white arrows). CMR findings are highly suggestive of inflammatory pericarditis without evidence of associated pericardial effusion 
(“dry pericarditis”)
Fig. 11 This 72-year-old male was admitted with dyspnea, pleural fluid and cirrhosis. Horizontal long-axis T1-weighted fast spin echo imaging 
shows (a) shows a focally thickened pericardium (black arrow) focally constricting the apical half of the right ventricle (RV). Horizontal long-axis 
cine imaging (b) confirms the constriction of the RV apex by the thick pericardium (white arrow). Presence of a moderate tricuspid regurgitation, 
bilaterally dilated atria, and right-sided pleural effusion, indirect findings compatible with constrictive pericarditis. The patient underwent 
successfully a pericardectomy
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but high signal at T2-weighted images with well-defined 
borders. CMR is helpful to differentiate this entity with 
other cystic structures arising in the chest (bronchogenic, 
esophageal duplication, thymic). Congenital absence of 
the pericardium is an extremely rare entity. Protrusion 
of a portion of the heart through the defect—usually left-
sided—causes an abnormal left to posterior location of 
heart. This observation—in the lack of other explanations 
for the abnormal positioning—should rise the possibility 
of a congenital defect [314, 315]. Defining the defect as 
such is more difficult as the pericardium along the LV is 
often not well visible due to the lack of surrounding fat. 
Repositioning the patient in right lateral decubitus may 
be very helpful to show the dynamic nature of this dis-
ease with (near-)normalization of the cardiac configura-
tion/position [327].
Cardiac masses
Primary tumours of the heart and pericardium, with the 
exception of atrial myxomas, occur rarely; metastatic 
tumors to or directly invasive of the heart are far more 
common [328, 329]. In adults the majority of primary 
tumors are benign with atrial myxomas being the most 
common. Other benign tumors include rhabdomyomas, 
fibromas, papillary fibroelastomas, hemangiomas, lipo-
mas, hamartomas, teratomas and pericardial cysts [328, 
329]. The malignant tumors consist of various sarcomas: 
myxosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, 
leiomyosarcoma, osteosarcoma, synovial sarcoma, rhab-
domyosarcoma, undifferentiated sarcoma, lymphoma, 
neurofibrosarcoma, and malignant fibrous histiocytoma 
[328, 329]. Benign tumours in infants and children are 
mainly teratoma, myxoma, fibroma and rhabdomyoma 
while malignant tumours include rhabdomyosarcoma, 
germ cell tumour and fibrosarcoma [330, 331].
Cardiac tumors produce a wide spectrum of symp-
toms through a number of mechanisms. Their size can 
obstruct intracardiac blood flow or interfere with valve 
function. Local invasion can lead to arrhythmias or peri-
cardial effusions with tamponade. Fragments of tumor 
can embolize, causing systemic deficits when the tumors 
are on the left side of the heart and pulmonary infarcts 
on the right side. Finally, the tumors may cause systemic 
or constitutional symptoms. Some tumors, produce no 
symptoms and become evident as incidental findings.
While TTE remains the first line imaging modality 
used in patients suspected of an intracardiac tumour or 
mass, this technique has several limitations and is highly 
dependent upon availability of good TTE “window” and 
even then, may not be able to provide a comprehensive 
answer due to limited field of view and inability to char-
acterize tissue. Positron emission tomography (PET) can 
also be used to characterize cardiac masses, but it has 
limited availability and limited spatial resolution and only 
in combination with the anatomic information of CT has 
it become a valuable tool for a variety of oncologic indi-
cations [332]. CMR has evolved as a reference standard 
method for the assessment of suspected cardiac tumours 
and is being increasingly used for confirmation and local-
ization, assessment of size, shape, attachment point and 
relation to surrounding structures as well as the haemo-
dynamic impact and tissue characterization of cardiac 
masses that may have been discovered using other types 
of imaging (Table  6). It is a versatile imaging method 
that provides 2D or 3D imaging using a variety of pulse 
sequences for a comprehensive assessment of cardiac 
tumours and related cardiovascular complications and 
is helpful in determining prognosis and treatment plan-
ning intervention (Figs.  12, 13) [333–335]. Serial CMR 
studies can be used to evaluate tumour growth, as well 
as assessment of resection and to monitor recurrence 
after surgery and to assess regression or progression 
after chemotherapy or radiotherapy [336, 337]. In addi-
tion to this, several CMR features can assist in tumour 
characterization [333, 334]. The signal intensity of a 
lesion is dependent on the interaction of the tissue com-
position and the CMR parameters employed for imag-
ing. The differential diagnosis of a high signal intensity 
lesion on T1-weighted images, corresponding to a short 
T1 relaxation time value, includes fatty tumours (lipoma, 
Table 6 Indications for CMR of cardiac masses
Indication Class
1. Suspected cardiac mass I
2. Differentiation between benign, malignant and non-tumourous masses I
3. Guide surgery and/or biopsy if this is deemed appropriate I
4. Follow-up of benign cardiac tumours that do not require urgent intervention for changes over time I
5. Evaluation of tumour resection/debulking, monitoring recurrence after surgery and regression or progression after chemotherapy or radio-
therapy
I
6. Extra-cardiac extension of cardiac tumours or cardiac extension of tumours originating from surrounding structures I
7. Impact of cardiac masses on hemodynamics I
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liposarcoma), recent haemorrhage (due to methaemo-
globin breakdown products) and melanoma (due to the 
effects of melanin). A lesion with low signal intensity on 
T1-weighted images may represent a cyst filled with low 
protein fluid, a signal void in a vascular malformation, 
a calcified lesion or the presence of air. Cysts typically 
have high signal intensity on T2-weighted images, corre-
sponding to a long T2 relaxation time value, independent 
of the protein concentration of the fluid. Tumours with 
high vascularity such as haemangioma also have high 
signal intensity on T2 weighted images while fibroma 
exhibits low signal intensity on this sequence. Fat satura-
tion suppress fat signal and can be used to diagnose fatty 
content definitively or better using fat/water separated 
images [338].
Further differentiation of the tumour can be made 
with GBCA which can be used in various ways [333–
337]. During the first pass of GBCA, vascular tumours 
show early enhancement and small vessels may be eas-
ily identifiable. The first pass enhancement is particu-
larly avid in haemangioma and to a lesser extent in 
angiosarcoma particularly if there is extensive necrosis 
and destruction of capillary bed. In the early phase, 
after injection at 1–2 min, necrotic areas in malignant 
tumours show as dark areas surrounded by enhance-
ment elsewhere. In the later phase (typically 10  min 
after injection), benign tumours such fibroma and 
haemangioma characteristically show strong almost 
homogenous enhancement while malignant tumours 
typically show heterogenous contrast enhancement 
indicating vascularity or GBCA leak age into a necrotic 
or fibrotic compartment. Such enhancement is usu-
ally absent in cystic lesions. Thrombus in the ventricles 
is well shown by modern CMR sequences, including 
bSSFP cines, and LGE [339] and for this CMR applica-
tion may be more sensitive than echocardiography even 
with echocardiographic contrast [340–342]. CE-CMRA 
provides additional information about primary or sec-
ondary vascular involvement. Intracardiac tumour 
mobility and its attachment points are best assessed by 
cine bSSFP while phase-contrast flow mapping is very 
useful for evaluation of the haemodynamic impact of 
cardiac tumours. More recently native T1 and T2 map-
ping have been used as adjunct techniques for tissue 
Fig. 12 Left atrial sarcoma (undifferentiated) obstructing mitral inflow (upper left: diastolic frame from bSSFP cine). T1W turbo spin-echo image 
shows the mass isointense relative to the myocardium (upper right) and hyperintense on short tau inversion recovery (STIR) T2 image (lower left). 
Extensive patchy enhancement within the mass is seen on LGE compatible with necrosis in this setting (lower right)
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characterization of cardiac tumours and masses [343]. 
Further development of PET/CMR scanners enabling 
combined high-sensitivity molecular imaging with high 
soft-tissue contrast and spectroscopic information, may 
have an important impact on the localization and dif-
ferentiation of tumors [344].
Finally, it is important to recognize the difference 
between structures normally present in the heart, which 
may be mistaken as a cardiac mass, and true cardiac 
masses. Structures that are normally present in the heart 
but are sometimes misinterpreted as pathology are [333]:
1 Crista terminalis, seen as a muscular ridge at the 
entry site of the superior vena cava into the right 
atrium, demarcating the part of the right atrium that 
is embryologically derived from the sinus venosus.
2 Eustachian valve, variably present in the right atrium 
as a remnant structure, after conveying blood toward 
the foramen ovale during fetal life.
3 “Coumadin ridge” at the confluence of the left upper 
pulmonary vein and the  left atrial appendage which 
can sometimes be bulbous. This is easily recognized 
by CMR but it can sometimes be misinterpreted as a 
thrombus or mass particularly with TTE .
4 Chiari network in the right atrium.
5 The moderator band of the RV that uniquely identi-
fies the anatomical RV;
6 False tendons of the LV.
Valvular heart disease
CMR has unique capabilities which can greatly enhance 
the assessment of valvular heart disease. TTE will likely 
remain the first-line and most common imaging modal-
ity for assessing valve disease, and AHA/ACC and ESC 
guidelines recommend CMR when echocardiographic 
assessment is unable to provide sufficient information. 
However, there are many areas where CMR provides 
‘added value’ to echocardiographic assessment in valve 
disease and can be complementary. Further, CMR can 
provide a comprehensive ‘stand-alone’ assessment in sev-
eral situations, delivering optimal assessment of patients 
using a combination of techniques, and for some valve 
lesions it is the most accurate method of assessment 
(Table 7).
Cine CMR with bSSFP sequences provides high res-
olution imaging of valve anatomy and function, par-
ticularly utilising the high contrast between the valve 
leaflets and the blood pool (Fig. 14). Care is required to 
position the imaging plane perpendicular to the valve 
Fig. 13 Large right ventricular fibroma attached to the entire ventricular septum. Diastolic frame from bSSFP cine (upper left). T1W fast spin-echo 
image (upper right) and STIR T2 image (lower right) show hypointense mass with very well defined borders and a thin rim of myocardium. LGE 
(right lower) shows extensive almost homogenous enhancement of the mass due to high fibrous/collagen content
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leaflets to minimise partial volume effects, but this is 
readily achieved. Excellent visualisation of the inflow 
and outflow tracts for both ventricles provide a full 
assessment of the location and nature of any obstruc-
tion. Additional information on the great vessels (aorta 
and pulmonary trunk) provides important information 
on the aetiology of aortic and pulmonary valve disease 
and the surrounding anatomy, to inform clinical man-
agement. CMR is especially helpful for areas that can 
be difficult to view with echocardiography, such as the 
pulmonary valve/trunk or the ascending aorta and is 
also feasible in larger patients without compromising 
image quality or visualisation of the relevant area.
Phase contrast velocity mapping delivers trans-valvar 
velocity, similarly to echo, with the advantage of not rely-
ing on alignment of the flow jet with the Doppler beam 
from the external chest wall (Fig.  15). However, the 
major advantage over all other imaging techniques, and 
a unique feature of CMR, is the ability of this sequence to 
quantify flow. This facilitates true quantitation of regur-
gitant valve lesions, rather than qualitative grading based 
on arbitrary thresholds.
Finally, accurate and reproducible quantification of LV 
and RV volumes, mass and function using CMR allows 
assessment of the effect of the valve lesion(s) on each 
ventricle and can be monitored over time.
Regurgitation
Mild regurgitation is usually well assessed with echocar-
diography and in general does not require CMR assess-
ment. The greatest utility of CMR lies in distinguishing 
moderate and severe regurgitation—this can be difficult 
with echocardiography, especially for aortic regurgita-
tion and pulmonary regurgitation with eccentric jets, and 
also where valve anatomy is non-standard (eg bicuspid 
valves, cleft mitral valves). Where discrepancy or uncer-
tainty about the degree of regurgitation exists, CMR can 
usually provide a  quantitative  answer. Aortic regurgita-
tion and pulmonary regurgitation are straightforward to 
assess with CMR, using phase contrast velocity mapping 
in a slice located just distal to the valve, and the regur-
gitant volume and regurgitant fraction (regurgitant vol-
ume/forward volume) can be quantified. It is important 
to use a reliable correction method for the background 
Table 7 Indications for CMR in valvular heart disease
Indication Class
1. Aortic stenosis II
2. Identification of sub- and supravalvular stenosis I
3. Aortic regurgitation II
4. Ascending aortic flow patterns in aortic stenosis Inv
5. Mitral stenosis III
6. Mitral regurgitation II
7. Pulmonary stenosis I
8. Pulmonary regurgitation I
9. Tricuspid stenosis III
10. Tricuspid regurgitation II
11. Prosthetic valve disease II
Fig. 14 Moderate aortic stenosis (short axis cine bSSFP image 
through the aortic valve tips in systole)—demonstrating the ease and 
reliability of direct planimetry to measure the valve area
Fig. 15 4D flow image demonstrating the extreme helical flow 
pattern in the ascending aorta of a patient with a bicuspid aortic 
valve
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flow offset error that can occur, such as the interpolated 
background flow correction technique. Quantifying 
mitral regurgitation or tricuspid regurgitation is gen-
erally performed using an indirect approach, subtract-
ing aortic flow or pulmonary flow (obtained from flow 
mapping) from LV or RV stroke volumes, respectively 
(using whole-heart volumetric cine assessment) [345]. 
This technique has the advantage of not being affected by 
regurgitant jets that are multiple, eccentric and/or varia-
ble through systole. Newer sequences with valve tracking 
software and/or 4D flow can be used for direct regurgita-
tion quantification, but these are less well established and 
available, and their reliability has not been comprehen-
sively assessed.
Quantifying aortic regurgitation with CMR has been 
shown to predict the future development of symptoms 
[346], and performed significantly better than TTE. Simi-
lar predictive ability has been demonstrated for the quan-
tification of mitral regurgitation with CMR [347, 348], 
and echocardiography was shown to have a consistent 
tendency towards over-estimation of the degree of mitral 
regurgitation [347, 349]. Mitral regurgitation quanti-
fication was also strongly associated with LV remod-
eling after valve repair/replacement [349]. Visualisation 
of the mitral valve with bSSFP cine imaging provides a 
similar level of information on anatomy and function 
as TEE [350], and also provides good assessment of the 
mitral regurgitant orifice in functional mitral regurgita-
tion [351]. Pulmonary regurgitation is straightforward 
to quantify and combined with good visualization of the 
RV outflow tract, CMR is the optimal technique for this 
lesion (for example in patients with repaired tetralogy 
of Fallot). In future, evolving techniques such as 4D flow 
imaging may facilitate accurate direct flow assessment in 
regurgitant lesions.
Stenosis
CMR can assess any valve stenosis, although is most com-
monly used for aortic stenosis and pulmonary stenosis. 
This is best achieved with a bSSFP cine imaging slice at 
the valve tips in systole (or diastole for mitral or tricuspid 
stenosis), which provides clear visualization of the degree 
of stenosis, and the valve area can be accurately meas-
ured from this [352], even with angulated outflow tracts. 
Although the anatomical valve area is often slightly larger 
than the valve area assessed by echocardiographic conti-
nuity equation, it remains a valuable technique. Velocity 
mapping adds to this with an assessment of the haemo-
dynamic severity of the stenosis. At higher velocities 
(> 3-4  m/s), accuracy is reduced due to signal loss from 
turbulence and phase shift errors from intra-voxel accel-
eration and dephasing, although ultra-short echo-time 
velocity mapping sequences may improve accuracy in 
high velocity jets [353], where these are available. Pul-
monary stenosis can be difficult to assess with echocar-
diography in adults, due to limited acoustic windows 
and the parallel direction of the RV outflow tract with 
the sternum, but this is easily assessed with CMR which 
is the optimal method for assessing pulmonary stenosis. 
Sub- and supra-valvar aortic and pulmonary stenosis (e.g. 
sub-aortic membranes) can also be seen easily with CMR 
bSSFP cine imaging. The presence of myocardial fibrosis 
on LGE in aortic stenosis has been associated with future 
events [354] but the clinical utility of this finding requires 
further study.
Prosthetic valves
Virtually all prosthetic valves and rings are safe in both 
1.5 T and 3 T CMR scanners, and CMR assessment can 
be valuable where not adequately assessed by echo-
cardiography. Most valves create a signal void artefact, 
although the degree is variable and depends on the type 
and amount of metal in the valve or frame. bSSFP or gra-
dient echo cine imaging can visualize prosthetic leaflet 
opening in selected bioprosthetic valves, as well as dem-
onstrate valve rocking, paravalvar leaks, abscesses and 
aneurysms where present. Flow quantification beyond 
the artefact from the valve can quantify forward veloc-
ity (for assessment of stenosis) and forward/reverse flow 
for regurgitation quantification, including the location of 
the leak. In selected cases, focused regions of interest for 
flow mapping can quantify the individual components of 
regurgitation (eg valvar vs paravalvar or each paravalvar 
leak if > 1 are present) to aid clinical treatment decisions.
Conclusions
CMR is one of the most powerful diagnostic tools in 
modern medicine and can provide highly reliable and 
actionable information for diagnosis and treatment 
across the spectrum of cardiovascular diseases. The high 
pace of technical advancements has led to a continuous 
expansion of the diagnostic capabilities and indications 
for CMR. In this Society for Cardiovascular Magnetic 
Resonance Consensus Panel report we provide a con-
temporary review of indications for CMR. The SCMR 
intends to update this document frequently with infor-
mation about new CMR techniques and results of studies 
and trials that lead to new or altered indications for clini-
cal CMR.
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